EGFR and non-small cell lung carcinoma: The aim of the study was to investigate, in terms of overall survival (OS) and progression free survival (PFS), the role of KRAS mutations in advanced EGFR wild-type NSCLC patients treated with first-line platinum-based chemotherapy.